Clinical Study Data Request Registered Users, Please Login

Scroll down the list of studies provided below. Studies are listed by study medicine in alphabetical order. Alternatively you can browse the list of studies using the search function.

To select studies and submit a research proposal or enquiry, go back to the Home page and select View and submit.

This takes you back to the previous page to enable you to view studies from a different sponsor.

Select medicine, medical condition or phase from the drop down boxes. This searches all the available clinical studies. Selecting from more than one drop down box will “and” the criteria.

Find by:


Alternatively search for studies using the Novartis Clinical Study Identification Number or study title by entering text and clicking search.

 

78 found

Click the study title to find more information about the study.

NOVARTIS-CCIB002I2301
A Prospective, Multinational, Multicenter Trial to Compare the Effects of Amlodipine/Benazepril to Benazepril and Hydrochlorothiazide Combined on the Reduction of Cardiovascular Morbidity and Mortality in Patients With High Risk Hypertension

Medicine: amlodipine/benazepril hcl, Condition: Hypertension, Phase: 3, Clinical Study ID: CCIB002I2301, Sponsor: Novartis
NOVARTIS-C-10-033
Three Month Efficacy and Safety Study of a Fixed Combination of Brinzolamide 1 %/Brimonidine 0.2 % Compared to Brinzolamide 1 % and Brimonidine 0.2 % All Dosed Three Times Daily in Patients With Open-Angle Glaucoma and/or Ocular Hypertension

Medicine: brinzolamide, Condition: Open-Angle Glaucoma; Ocular Hypertension, Phase: 3, Clinical Study ID: C-10-033, Sponsor: Novartis
NOVARTIS-C-10-039
A Three-Month, Randomized, Double-Masked, Parallel-Group Study with a Planned Three-Month Safety Extension of the Efficacy and Safety of a Fixed Combination of Brinzolamide 1 %/Brimonidine 0.2 % Compared to Brinzolamide 1 % and Brimonidine 0.2 % All Dosed Three Times Daily in Patients with Open-Angle Glaucoma and/or Ocular Hypertension

Medicine: brinzolamide, Condition: Open-Angle Glaucoma; Ocular Hypertension, Phase: 3, Clinical Study ID: C-10-039, Sponsor: Novartis
NOVARTIS-C-10-040
Safety and IOP-Lowering Efficacy of Brinzolamide 10 mg/mL/Brimonidine 2 mg/mL Fixed Combination Eye Drops, Suspension Compared to Brinzolamide 10 mg/mL Eye Drops, Suspension and Brimonidine 2 mg/mL Eye Drops, Solution in Patients With Open-Angle Glaucoma or Ocular Hypertension

Medicine: brinzolamide, Condition: Open-Angle Glaucoma; Ocular Hypertension, Phase: 3, Clinical Study ID: C-10-040, Sponsor: Novartis
NOVARTIS-C-10-041
Efficacy and Safety of Brinzolamide 10 mg/mL/Brimonidine 2 mg/mL Eye Drops, Suspension Compared to Brinzolamide 10 mg/mL Eye Drops, Suspension Plus Brimonidine 2 mg/mL Eye Drops, Solution in Patients With Open-Angle Glaucoma or Ocular Hypertension

Medicine: brinzolamide, Condition: Open-Angle Glaucoma; Ocular Hypertension, Phase: 3, Clinical Study ID: C-10-041, Sponsor: Novartis
NOVARTIS-CLDK378A2201
A Phase II, Multicenter, Single-arm Study of Oral LDK378 in Adult Patients With ALK-activated Non-small Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib

Medicine: ceritinib, Condition: Non-small cell lung carcinoma (NSCLC), Phase: 2, Clinical Study ID: CLDK378A2201, Sponsor: Novartis
NOVARTIS-CLDK378X2101
A Phase I, Multi-center, Open Label Dose Escalation Study of LDK378, Administered Orally in Adult Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase (ALK)

Medicine: ceritinib, Condition: Tumors Characterized by Genetic Abnormalities of ALK, Phase: 1/2, Clinical Study ID: CLDK378X2101, Sponsor: Novartis
NOVARTIS- BRF113929
BRF113929: An Open-Label, Two-Cohort, Multicentre Study of GSK2118436 as a Single Agent in Treatment Naïve and Previously Treated Subjects With BRAF Mutation-Positive Metastatic Melanoma to the Brain

Medicine: dabrafenib, Condition: Melanoma, Phase: 2, Clinical Study ID: BRF113929, Sponsor: Novartis.
NOVARTIS-TPL104054
Randomised, Double-Blind, Placebo-Controlled, Multi-Centre Study to Evaluate the Safety and Efficacy of Eltrombopag to Reduce the Need for Platelet Transfusion in Thrombocytopenic Subjects with Chronic Liver Disease Undergoing Elective Invasive Procedures

Medicine: eltrombopag, Condition: Liver Diseases, Phase: 3, Clinical Study ID: TPL104054, Sponsor: Novartis
NOVARTIS-CRAD001R2301
A Randomized, Double-blind, Multi-center Phase III Study Comparing Everolimus (RAD001) Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Patients With Advanced Gastric Cancer After Progression on 1 or 2 Prior Systemic Chemotherapy

Medicine: everolimus, Condition: Cancer, Advanced Gastric, Phase: 3, Clinical Study ID: CRAD001R2301 , Sponsor: Novartis.
First Previous 1 2 3 4 5 6 7 8 Next Last